Companies developing a new class of diabetes drugs known as DPP-4 inhibitors have presented possible alternatives to Januvia, an FDA-approved treatment from Merck & Co., at the American Diabetes Association meeting. Researchers said that saxagliptin, Bristol-Myers Squibb Co. and AstraZeneca's candidate, helped more than one-third of patients reach the recommended glucose level in a six-month study. A combination of Takeda Pharmaceutical Co.'s alogliptin and Actos, an older drug, reduced glucose levels better than placebo and seemed as effective as Januvia, analysts said.

Full Story:

Related Summaries